Trial | NCT01808768  Report issue

Title

Ocular Allergy Treatment Practical Impact Trial
To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    50
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)
Study Started
Apr 30
2013
Primary Completion
Oct 31
2013
Anticipated
Study Completion
Nov 30
2013
Anticipated
Last Update
May 30
2013
Estimate

Drug Alcaftadine

Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.

  • Other names: Lastacaft

Alcaftadine Experimental

subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks

Criteria 

Inclusion Criteria:

patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
Are willing/able to follow instructions from the study investigator and his/her study staff.

Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.

-

Exclusion Criteria:

Active ocular infection;
History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
History of unstable, or uncontrolled disease of any nature.
Pregnancy or lactation;
Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -
No Results Posted